FDA approves first cell therapy to treat aggressive forms of melanoma

Amtagvi is the first cell therapy for solid tumors approved by the FDA. (Iovance Biotherapeutics, Inc.)

The Food and Drug Administration has approved a novel type of cancer therapy to treat aggressive forms of melanoma using immune system cells from a patient's tumor.

The treatment, called Amtagvi, was developed by Iovance Biotherapeutics, a biotech company based in San Carlos, Calif.